From the Guidelines
Meropenem is effective against urinary tract infections (UTIs) caused by E. coli, including extended-spectrum beta-lactamase (ESBL) producing strains, as recommended by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines 1.
Key Points to Consider
- Meropenem is typically administered intravenously at a dose of 500 mg to 1 gram every 8 hours for complicated UTIs, with the duration usually ranging from 7 to 14 days depending on infection severity 1.
- For patients with renal impairment, dose adjustment is necessary based on creatinine clearance.
- Meropenem works by inhibiting bacterial cell wall synthesis and is particularly valuable for ESBL-producing organisms because, as a carbapenem antibiotic, it remains stable against these beta-lactamase enzymes that would normally break down many other antibiotics like penicillins and cephalosporins.
- While meropenem is highly effective, it's typically reserved for serious infections or when other antibiotics have failed, to prevent development of resistance.
- Common side effects include headache, nausea, diarrhea, and injection site reactions.
- Patients should complete the full course of treatment even if symptoms improve before completion.
Evidence Supporting Meropenem Use
- The ESCMID guidelines recommend a carbapenem (imipenem or meropenem) as targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3GCephRE, which includes ESBL-producing E. coli 1.
- A study comparing intravenous fosfomycin with meropenem for the treatment of bacteraemic complicated UTI caused by E. coli, including ESBL-producing strains, showed no significant differences in clinical or microbiological cure between the two groups 1.
Considerations for Use
- Meropenem should be used with caution in patients with renal impairment, and dose adjustment is necessary based on creatinine clearance.
- The risk of developing resistance to meropenem and other carbapenems is a concern, and their use should be reserved for serious infections or when other antibiotics have failed.
- Patients should be monitored for common side effects, including headache, nausea, diarrhea, and injection site reactions, and the full course of treatment should be completed even if symptoms improve before completion.
From the Research
Effectiveness of Meropenem against UTI with E. coli and ESBL
- Meropenem is a broad-spectrum antibacterial agent that has been shown to be effective against extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, including E. coli 2.
- The study found that meropenem has a broad spectrum of in vitro activity against Gram-positive and Gram-negative pathogens, including ESBL- and AmpC-producing Enterobacteriaceae 2.
- Meropenem is recommended as a parenteral treatment option for UTIs due to ESBLs-producing Enterobacteriales, including E. coli 3.
- Another study found that carbapenems, such as meropenem, are the most effective agents against ESBL-producing E. coli and Klebsiella pneumoniae 4.
- A clinical trial is being conducted to compare the efficacy of meropenem with fosfomycin in treating bacteraemic urinary tract infections caused by ESBL-producing E. coli 5.
Meropenem/Vaborbactam Combination
- The combination of meropenem and vaborbactam has been approved for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis 6.
- Vaborbactam is a potent inhibitor of class A serine carbapenemases, which restores the activity of meropenem against β-lactamase producing Enterobacteriaceae 6.
- The meropenem/vaborbactam combination has demonstrated excellent in vitro activity against Gram-negative clinical isolates, including KPC- and ESBL-producing Enterobacteriaceae 6.
- A phase 3 clinical trial found that meropenem/vaborbactam was noninferior to piperacillin/tazobactam for overall success and microbial eradication in patients with cUTIs 6.